Title |
Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis
|
---|---|
Published in |
Cancer Immunology, Immunotherapy, April 2014
|
DOI | 10.1007/s00262-014-1554-7 |
Pubmed ID | |
Authors |
Masanori Kobayashi, Shigetaka Shimodaira, Kazuhiro Nagai, Masahiro Ogasawara, Hidenori Takahashi, Hirofumi Abe, Mitsugu Tanii, Masato Okamoto, Sun-ichi Tsujitani, Seiichi Yusa, Takefumi Ishidao, Junji Kishimoto, Yuta Shibamoto, Masaki Nagaya, Yoshikazu Yonemitsu, The DC Vaccine Study Group at the Japan Society of Innovative Cell Therapy (J-SICT) |
Abstract |
Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced pancreatic cancer. However, variations among clinical studies make it difficult to compare clinical outcomes. Here, we identified factors that determined the clinical benefits by analyzing data obtained at seven Japanese institutions that employed the same DC preparation and treatment regimens. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 40 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 25% |
Other | 7 | 18% |
Student > Bachelor | 3 | 8% |
Student > Postgraduate | 3 | 8% |
Student > Master | 3 | 8% |
Other | 6 | 15% |
Unknown | 8 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 33% |
Immunology and Microbiology | 5 | 13% |
Psychology | 3 | 8% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Chemistry | 2 | 5% |
Other | 6 | 15% |
Unknown | 9 | 23% |